Loading organizations...
§ Venture Capital · Seattle, WA, USA
Biotechnology company developing clinical diagnostics & research tools for immune-driven diseases, focused on MRD.
Seattle-based Adaptive Biotechnologies maps the genetics of the adaptive immune system to develop clinical diagnostics and personalized therapeutics for oncology, immunology, and infectious diseases. The publicly traded company sequences T-cell and B-cell receptors to power its core commercial products, including the FDA-cleared clonoSEQ assay for detecting minimal residual disease in blood cancers and the immunoSEQ research platform. To advance its immune-driven medical research, the organization collaborates with major biopharmaceutical and technology partners, maintaining strategic alliances with Microsoft for artificial intelligence applications and Genentech for targeted therapeutic development. Operating with approximately 700 employees across its operations, the enterprise generated $170.3 million in full-year 2023 revenue and achieved a valuation exceeding $1 billion during its 2019 initial public offering on the Nasdaq exchange. Adaptive Biotechnologies was originally founded in 2009 by brothers Chad Robins and Harlan Robins.
Adaptive Biotechnologies has raised $414.8M across 5 funding rounds.
Key people at Adaptive Biotechnologies.
Adaptive Biotechnologies was founded in 2009 by Harlan Robins (Head of Innovation, Co-founder) and Chad Robins (Co-Founder, President & CEO).
Adaptive Biotechnologies has raised $414.8M in total across 5 funding rounds.
Adaptive Biotechnologies has raised $414.8M across 5 funding rounds. Most recently, it raised $15.0M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 30, 2025 | $15M Series A | — | — | Announced |
| May 7, 2015 | $195M Series F | David Goel | — | Announced |
| Jan 7, 2015 | $94M Venture Round | Viking Global Investors | — | Announced |
| Apr 7, 2014 | $105M Series C | Viking Global Investors | — | Announced |
| Jun 10, 2011 | $5.8M Series B | — | — | Announced |
Key people at Adaptive Biotechnologies.
Adaptive Biotechnologies was founded in 2009 by Harlan Robins (Head of Innovation, Co-founder) and Chad Robins (Co-Founder, President & CEO).
Adaptive Biotechnologies has raised $414.8M in total across 5 funding rounds.
Adaptive Biotechnologies's investors include David Goel, Viking Global Investors.